Janssen to work with Medopad on developing digital test for Alzheimer's

Janssen Pharmaceuticals is set to work with health technology company Medopad on a project to develop a digital biomarker test for Alzheimer’s disease.

The collaboration will examine how Janssen’s digital ReVeRe platform can be used to assess and monitor the verbal memory of patients at risk of Alzheimer’s disease.

Janssen Pharmaceuticals’ ReVeRe platform works on an iPad and automates the administration and scoring of the Rey Auditory Verbal Learning Test (RAVLT) - along with other tests of attention and executive function known to be relevant in early stages of AD.

Medopad will use its experience in implementing and scaling digital healthcare solutions across the National Health Service (NHS) and other international health systems to potentially allow the ReVeRe technology to be deployed across patient populations in both the UK and China.

The goal is to roll it out as a home-based, validated automated congnitive tool that could facilitate unsupervised and reliable longitudinal assessment of early cognitive decline due to AD within a real-world environment. 

Dan Vahdat, Medopad CEO and founder, said: “We are excited to further expand the validation for potential commercialisation of this technology. Once we have concluded implementation and final testing, we aim to be able to screen an entire nation for Alzheimer’s disease at low cost. This project is one of the many Medopad is currently undertaking and we see strategic collaborations like this as essential in accelerating us to achieve our vision of creating a world where people can live longer, fuller lives.”